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Abstract
Background: HIV-1 integrase (IN) is an attractive target for the development of drugs to treat AIDS, and
inhibitors of this viral enzyme are already in the clinic. Nevertheless, there is a continuing need to devise
new approaches to block the activity of this viral protein because of the emergence of resistant strains. To
facilitate the biochemical analysis of wild-type IN and its derivatives, and to measure the potency of
prospective inhibitory compounds, a rapid, moderate throughput solution assay was developed for IN-
catalyzed joining of viral and target DNAs, based on the detection of a fluorescent tag.
Results: A detailed, step-by-step description of the new joining assay is provided. The reactions are run
in solution, the products captured on streptavidin beads, and activity is measured by release of a
fluorescent tag. The procedure can be scaled up for the analysis of numerous samples, and is substantially
more rapid and sensitive than the standard radioactive gel methods. The new assay is validated and its
utility demonstrated via a detailed comparison of the Mg++- and Mn++-dependent activities of the IN
proteins from human immunodeficiency virus type 1 (HIV-1) and the avian sarcoma virus (ASV). The
results confirm that ASV IN is considerably more active than HIV-1 IN, but with both enzymes the initial
rates of joining, and the product yields, are higher in the presence of Mn++ than Mg++. Although the pH
optima for these two enzymes are similar with Mn++, they differ significantly in the presence of Mg++, which
is likely due to differences in the molecular environment of the binding region of this physiologically
relevant divalent cation. This interpretation is strengthened by the observation that a compound that can
inhibit HIV-1 IN in the presence of either metal cofactors is only effective against ASV in the presence of
Mn++.
Conclusion: A simplified, assay for measuring the joining activity of retroviral IN in solution is described,
which offers several advantages over previous methods and the standard radioactive gel analyses. Based
on comparisons of signal to background ratios, the assay is 10–30 times more sensitive than gel analysis,
allows more rapid and accurate biochemical analyses of IN catalytic activity, and moderate throughput
screening of inhibitory compounds. The assay is validated, and its utility demonstrated in a comparison of
the metal-dependent activities of HIV-1 and ASV IN proteins.
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Background
Retroviral integrase (IN) catalyzes the insertion of a
duplex DNA copy of the viral RNA genome into the DNA
of its host cell. This process establishes the retroviral pro-
virus as a permanent component of the host cell genome,
and is required for normal viral gene expression via host
cell components. IN proteins are members of a super-
family of polynucleotidyl transferases, which include
transposases and other recombinases. The HIV-1 IN is of
special interest as a target for the development of drugs to
treat AIDS [1]. For both medical and scientific reasons
therefore, the biochemistry of IN proteins has been the
focus of intense investigation.
IN proteins catalyze two sequential and temporally dis-
tinct reactions during infection, see (Figure 1A) [2,3]. In
the first reaction, called processing, two nucleotides adja-
cent to a conserved CA dinucleotide are removed from the
3' end of newly synthesized viral DNA. The sequence near
the viral DNA ends determines the specificity for cognate
viral IN proteins. The processing reaction can take place in
the cytoplasm before the complex of viral DNA and IN
gains access to host DNA in the nucleus. Following
nuclear entry, the newly processed 3' ends of the viral
DNA are joined by IN to staggered sites on both strands of
the host DNA in a concerted cleavage and ligation reac-
tion. The joining reaction produces gaps in the host DNA
adjacent to the 5' ends of the viral DNA. The damage
incurred by formation of this intermediate is then
repaired by host cell enzymes, leading to stably integrated
proviral DNA [4]. The IN proteins of different viruses
exhibit distinct preferences for integration loci, but DNA
sequence per se, does not seem to be a major determining
factor [5-8]. For HIV-1, and likely other integrases and
transposases, interaction with host chromatin-bound pro-
teins plays an important role in such selection [9,10].
Therefore, both the catalytic activities and protein-protein
interactions of IN are critical for its function.
The development by Katzman et al. [11] of an oligodeox-
ynucleotide-based assay to study the biochemical proper-
ties of IN proteins in vitro was an important milestone in
the field (Figure 1B). In this assay, a short, radioactively
labeled DNA duplex comprising the sequence of either or
both viral DNA ends is incubated with the cognate IN pro-
tein. The processing and subsequent joining of the labeled
strand to self or other targets DNAs, can then be followed
by electrophoresis on sequencing gels, allowing all of the
substrates and products to be identified [12,13]. Since
these original reports, numerous variations on this assay
theme have been developed, including the substitution of
reporters other than radioactivity, and addition of modifi-
cations (e.g., biotin) that facilitate isolation of the prod-
ucts. Such variations have allowed for the development of
high throughput screens for inhibitors, and have facili-
tated the analysis of each step in the reaction. Neverthe-
less, for many research laboratories, radioactive substrates
and gel assays are still employed, despite the fact that such
methods are laborious, time-consuming, and not well-
suited for kinetic analyses or investigations that require
the testing of a large number of proteins or reaction
parameters. This problem was alleviated partially through
the development of a fluorescence anisotropy assay, to
study the DNA binding and processing activities of IN
[14].
More recently, we have developed a rapid, sensitive, and
simplified fluorescence-based assay to study the joining
activity of IN proteins in solution. In this report we
describe and validate the assay, and illustrate its utility in
a comparison of the joining properties of ASV and HIV-1
integrase, as well as their responses to inhibitory com-
pounds. A preliminary report of this method, together
with detailed protocols for fluorescence-based DNA bind-
ing and processing assays, has been published [15].
Methods
Protein preparation
The ASV and HIV-1 IN proteins used in these studies were
purified from the soluble fraction of bacterial lysates after
expression of untagged versions of the proteins from plas-
mid vectors. Similar procedures were employed for both
proteins and no detergents were used during the purifica-
The retroviral DNA integration reaction Figure 1
The retroviral DNA integration reaction. Panel A. The 
processing and joining steps catalyzed by retroviral integrases 
produce a gapped recombination intermediate. The shaded 
region represents an IN multimer, heavy lines the viral DNA, 
and thin lines host DNA. The position of the conserved CA 
dinucleotides at the ends of the viral DNA is shown and the 
position of the processing cleavage sites are marked with 
straight arrows. The curved arrows indicate the staggered 
phosphodiester bonds cleaved during the joining reaction. 
Panel B. Simple in vitro assays for IN activity represent reac-
tions at a single viral DNA end. Viral(donor) or host(target) 
DNAs are distinguished as in A. Filled circles mark the 5' 
phosphate ends and open circles the 3' hydroxyl ends.AIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
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tion, as previous reports have noted that they can affect
the multimeric state and the Mg++-dependent activities of
these enzymes [16].
The wildtype ASV IN protein used in these experiments
was expressed and purified as follows: Bacterial cells,
BL21 [DE3], containing the plasmid pET29 that expresses
wildtype ASV IN (Schmidt-Rupin B strain), were induced
to express IN, harvested from 1 liter of Luria broth culture
and stored frozen. The frozen cell pellets were thawed and
resuspended in lysis buffer (50 mM Tris-Cl pH 7.5, 4 M
NaCl, 1% thiodiglycol, 0.1 mM EDTA, 10% glycerol) at
0.1–0.2 g of wet cells/ml. The cells were lysed by two
passes through a French Pressure cell at 20,000 psi. The
lysate was then subjected to an overnight polyethylene
glycol (PEG-8000)-dextran phase separation at 4°C to
remove DNA, and the PEG phase was adjusted to 0.2 M
salt concentration by conductivity prior to batch purifica-
tion on phospho-cellulose (Whatman P11). After wash-
ing, IN was eluted with phospho-cellulose elution buffer
(50 mM Tris-Cl pH 7.5, 1.2 M NaCl, 1% TDG, 0.1 mM
EDTA, 10% glycerol). The fractions containing IN were
identified by SDS-polyacrylamide gel electrophoresis
(PAGE) and pooled. Aliquots were diluted five-fold to
reduce the final salt concentration to 0.2 M, and immedi-
ately applied to a 5 ml HiTrap heparin column equili-
brated with heparin binding buffer (50 mM Tris-l pH 7.5,
0.2 M NaCl, 10% glycerol). Following a wash step, the
bound protein was eluted with a gradient from 0.2 to 1.2
M NaCl in the same buffer. The fractions containing IN
were again identified by SDS-PAGE, pooled, concen-
trated, and dialyzed against three changes of 1 liter 50 mM
Hepes pH 8.1, 0.5 M NaCl, 1% thiodiglycol, 0.1 mM
EDTA, 1 mM dithiothreitol (DTT), 40% glycerol. Follow-
ing dialysis, aliquots were flash frozen in liquid nitrogen
at ~1–2 mg IN/ml. We note that wildtype ASV IN can also
be purified using the method described below for HIV-1
IN, with no significant difference in yield or specific
activity.
The HIV-1 IN protein was expressed and purified as fol-
lows: Bacterial cells, BL21 [DE3], containing the plasmid
pET29 that expresses wildtype HIV-1 IN (NY5 strain),
were induced to express IN, harvested from 1 liter of Luria
broth culture and stored frozen. The frozen cell pellets
were thawed and resuspended in lysis buffer (25 mM Bis-
Tris-HCl pH 6.1, 1 M NaCl, 1 M urea, 0.1 M imidazole,
5% glycerol with protease inhibitors (aprotinin, leupep-
tin, phenylmethyl sulfonyl fluoride, and pepstatin) at
0.13 g of cells/ml. The cells were lysed by passage through
a French Pressure cell as above, and the lysate was then
sonicated for 30 s. The preparation was subjected twice to
centrifugation for 30 min at 12,000 × g. Solid NaCl was
added to the supernatant fraction to bring it to 4 M con-
centration, and it was then applied to a 22 ml methyl
hydrophobic interaction chromatography column (Bio-
rad) equilibrated with HIC Buffer A (25 mM BisTris-HCl
pH 6.1, 1 M urea, 4 M NaCl, 0.1 M imidazole, 5% glyc-
erol, and 6 mM 2-mercaptoethanol). Following a brief
wash, the bound protein was eluted with a linear gradient
to HIC Buffer B (contents identical to HIC Buffer A with
the exception of 0.2 M NaCl). The fractions containing IN
were identified by SDS-PAGE. Protease inhibitors were
again added to these fractions and they were then pooled
in preparation for the second column step. Aliquots of
this pool were diluted to reduce the final salt concentra-
tion to 0.2 M, using a buffer containing 50 mM BisTris-
HCl pH 6.5, 1 M urea, 0.1 M imidazole, 5% glycerol with
6 mM 2-mercaptoethanol. This solution was immediately
applied to a 5 ml HiTrap heparin column equilibrated
with Heparin Buffer A (25 mM BisTris-HCl pH 6.1, 1 M
urea, 0.2 M NaCl, 0.1 M imidazole, 5% glycerol and 6 mM
2-mercaptoethanol). Following a wash step, the bound
protein was eluted with an exponential gradient of 0.2 to
1.2 M NaCl in the same buffer. The fractions containing
IN were identified by SDS-PAGE, pooled, concentrated,
and dialyzed against three changes of 1 liter 25 mM Bis-
Tris-HCl pH 6.1, 1 M NaCl, 1% thiodiglycol, 1 mM dithi-
othreitol (DTT), 40% glycerol. Following dialysis,
aliquots were flash frozen in liquid nitrogen at ~1–2 mg
IN/ml.
DNA substrates
Viral DNA (donor) oligodeoxynucleotides with a cova-
lently attached 6-carboxyfluorescein (6-FAM) were pur-
chased from Integrated DNA Technologies (Coralville,
IA), and purified by Tris-borate urea denaturing polyacry-
lamide gel electrophoresis. The efficiency of labeling was
quantified by comparison of the absorbance at 260 nm
with the peak absorbance of the fluorophore (495 nm for
6-FAM). The labeled oligodeoxynucleotides were
annealed with unlabeled complementary oligodeoxynu-
cleotides to obtain viral donor oligodeoxynucleotide
duplexes. Complementary strands of the target oligodeox-
ynucleotide containing biotin at their 3'-ends were syn-
thesized and purified in the Fox Chase DNA Synthesis
Facility. These were then annealed to obtain a 27 bp
duplex with single nucleotide overhang on each 3'-end to
which biotin was attached.
Fluorescence assays for enzymatic activities
Processing activity was measured using fluorescence-ani-
sotropy [14,15]. The fluorescence intensity assay for join-
ing (Figure 2A) was performed as follows:
Steps 1–2. Preincubation and reaction conditions
The double stranded, 6-FAM-labeled viral oligodeoxynu-
cleotide (donor substrate) was mixed with IN and the
metal cofactor, and the mixture was left on ice for 15 min.
The biotin-conjugated, double stranded target oligodeox-AIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
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ynucleotide was then added, and the mixture left on ice
for an additional 15 min, after which it was transferred to
a waterbath at 37°C and incubated for the desired period.
The total reaction volume was 20 μl. We determined the
optimal ratio of IN:viral oligodeoxynucleotide:target oli-
godeoxynucleotide, to be 4:1:6, and this ratio was used to
test the potency of the inhibitors. These reactions con-
tained 1 μM IN, 0.25 μM 6-FAM-labeled viral oligodeoxy-
nucleotide (26nt/28nt recessed duplex), 1.5 μM biotin-
conjugated target oligodeoxynucleotide duplex, 5 mM
DTT or 2 mM mercaptoethanol, 10% DMSO, 25 mM
Hepes, pH 7.5 (at 37°C) with 10 mM MnCl2 (Fisher, Cer-
tified ACS) or 10 mM MgCl2, (Fisher, Certified ACS) and
ionic strength ≤ 100 mM NaCl equivalents. The reactions
were stopped by the addition of 10 μl of 30 mM EDTA.
For the comparisons described in Figures 2 and 3, we used
a slightly sub-optimal ratio of 2:1:6 that allowed for the
detection of both increases and decreases in joining activ-
ity. These reactions contained 1 μM IN, 0.50 μM 6-FAM-
labeled viral oligodeoxynucleotide, and 3.0 μM biotin-
conjugated target oligodeoxynucleotide.
Step 3. Product capture
A 96 well filter plate (Pall Life Sciences; AcroPrep 96 filter
plate, 0.45 μm GHP membrane, 350 μl/well, PN 5030)
was prepared for use by adding 50 μl of a 1:1 slurry of
streptavidin agarose beads to each well (Invitrogen;
streptavidin agarose, sedimented bead suspension, PN
S951). The assay reactions were transferred to the wells,
and incubated at room temperature for 30 min (with gen-
tle shaking at 5 min intervals) to allow the biotin-conju-
gated target and joined products to bind to the beads. The
wells were then washed 10 times with 200 μl Wash Buffer
(1× PBS, 0.05% SDS, 1 mM EDTA) using a vacuum man-
ifold (Pall Life Sciences; Multi-well Plate Vacuum mani-
fold, PN5017). In some cases, the last wash was also
collected by centrifugation into a reader plate and ana-
lyzed to confirm that all of the unbound, unjoined FAM-
labeled viral oligodeoxynucleotide had been removed.
Step 4. Probe release
The viral oligodeoxynucleotide strand that included the 6-
FAM probe was dissociated from the bound product by
denaturation via addition of 150 μl of freshly prepared 50
mM NaOH to each well. The plate was then left at room
temperature for 5 min. The soluble fractions were col-
lected by centrifugation (2,000 × g/10 min) into a black,
round bottom 96 well plate (Costar, storage plate, PN
3356).
Moderate-throughput solution assay for integrase joining  activity Figure 2
Moderate-throughput solution assay for integrase 
joining activity. Panel A. Principles of a solution assay to 
measure integrase joining activity by fluorescence. Labeling 
and symbols are as in Figure 1. FAM stands for carboxyfluo-
rescein labeled DNA, a circle with B denotes a biotin modi-
fied 3' end in the target oligodeoxynucleotide. Panel B. 
Comparison of HIV-1 and ASV IN joining activities in Mg++ 
and Mn++. The dashed lines with squares show the activity of 
ASV IN and the solid lines with triangles show the activity of 
HIV-1 IN expressed as RFUs versus time. Filled and open 
symbols represent activity in Mn++ and Mg++, respectively. 
The inset shows results from the same experiment, after 40 
min. and up to 180 min. incubation. Panel C. Comparison of 
the joining activity of ASV IN with the recessed versus the 
blunt-ended donor oligodeoxynucleotides in the presence of 
Mg++ (recessed donor oligodeoxynucleotide, dashed line with 
filled squares; blunt-ended donor oligodeoxynucleotide, solid 
line with filled circles).
Joining activity confirmed with gel electrophoresis Figure 3
Joining activity confirmed with gel electrophoresis. 
Left, sequences of the donor oligodeoxynucleotides used in 
the joining assay. The location of carboxyfluorescein (FAM), 
5' radioactive 32P, and 3' biotin are shown. The -A substrate 
removes only the A of the conserved CA dinucleotide while 
the -CA substrate removes both residues. Right, lanes 1 
through 3 show HIV-1 IN joining activity on its substrate 
after 0, 60, 120 min of incubation, respectively. Lanes 4 
through 6, 7 through 9, and 10 through 12, show ASV IN 
joining activity after 0, 15, 30 min of incubation.AIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
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Step 5. Detection and analysis of the released product 
data
The wells were read using a Tecan GENois Pro fluorescent
microplate reader equipped with Magellan Standard
V5.03 software (Tecan Austria GmbH, Salzburg, Austria)
set to the fluorescence intensity mode. In this instrument
the excitation of 6-FAM is at 485 nm and the emission is
measured at 535 nm. The data from the plate scanner are
expressed as relative fluorescence units (RFUs). The exper-
imental RFU readings, including the data from the back-
ground wells and the controls were transferred to the
Visual Enzymics (Softzymics, Princeton, NJ) module run-
ning with Igor Pro (Wavemetrics, Inc.) graphing software.
In the experiments described in Figure 4, the IC50 values
were determined from non-linear fitting of the triplicate
data to a four parameter sigmoidal dose response equa-
tion:
where A is the activity at maximal inhibition, B is the
activity in the absence of inhibitor, X is the inhibitor con-
centration, C is the IC50 value, and D is the Hill coefficient.
The Hill coefficient, which is proportional to the slope of
the sigmoidal curve, reflects the cooperativity and the
tightness of binding of the inhibitor to the enzyme. All
four parameters are fitted, and the standard error and Chi
squared goodness of fit statistics confirm adequate data
quality. The data are then plotted as percent joining activ-
ity to compare the various enzymes, metals, and inhibi-
tors used.
Standard radioactive gel assays
The same viral donor DNAs were assembled after the
strand to be processed was 32P-labeled at its 5' end. These
strands were then annealed with complementary oligode-
oxynucleotides that were labeled with 6-FAM, as
described for the fluorescent assay above. The target DNA
and reaction conditions followed those described for the
fluorescent assay. The products were separated by electro-
phoresis in a Tris-borate-urea 20% polyacrylamide gel and
quantified using a Fuji phosphorimager. The processed
products migrated below the substrate bands, and the
joined products migrated in a series of bands above the
substrates.
Results
Principles of the fluorescence-based joining assay
This assay employs a short DNA duplex (e.g., 18–28 base
pairs) comprising the sequence at the end of one or the
other viral LTR, hereafter called the donor oligodeoxynu-
cleotide. As illustrated in Figure 2A, the 3' end of the
strand complementary to that which is cleaved by IN is
labeled with carboxyfluorescein (6-FAM). To study only
the joining reaction, the donor oligodeoxynucleotide has
a recessed CA end, as would normally be produced in the
processing reaction. The details of the assay, provided in
Methods, are outlined briefly in Figure 2A. In step 1, the
donor oligodeoxynucleotide is mixed with IN and the
required divalent metal cofactor (Mn++ or Mg++) in a suit-
able buffer on ice. The target oligodeoxynucleotide, which
contains biotin at both 3' ends, is then added in molar
excess over the donor. In step 2, the mixture is incubated
at 37°C for the desired period, after which catalysis is
stopped by the addition of an excess of EDTA. In step 3,
the reaction is transferred to a well in a 96 well filter plate
that contains a slurry of streptavidin agarose beads. This
mixture is left at room temperature for 30 min and shaken
gently at 5 min intervals. In step 4, the beads are washed
thoroughly with suction applied in a multi-well plate vac-
uum manifold. A solution of 50 mM NaOH is then added
to each well to denature the DNA and the mixture left for
5 min at room temperature. In step 5, the solution con-
taining the released FAM-labeled donor single strands is
collected by centrifugation into a 96 well plate. The fluo-
rescence of the FAM-labeled donor in each well is
recorded in a plate reader.
During optimization studies, we measured the relative
activities of ASV and HIV-1 IN in the presence of both
cofactors, and observed an increase with increasing diva-
lent metal concentration to a maximum at approximately
15 mM for both proteins. We note that higher metal con-
centrations promote the non-specific endonuclease of IN
proteins and can raise the ionic strength to inhibitory lev-
els. To avoid these problems and to establish uniform
conditions for our comparisons we chose the close to
optimum concentration of 10 mM to measure the joining
activities of these two proteins.
The pH-dependence of both the processing and the join-
ing reactions with ASV and HIV-1 IN proteins in the pres-
ence of either Mn++ or Mg++ was also determined. The
results from our joining assays indicated that with Mn++ as
cofactor, both enzymes exhibit activity maxima in the
range of pH 7–7.5; maxima for processing with Mn++ are
higher, at pH 8.1 for both enzymes. Rather different
results were obtained with Mg++ as cofactor. In this case,
optima for ASV IN were in the range of pH 8–8.5 for both
processing and joining, whereas the optima for HIV-1 IN
were substantially lower, pH 7 for processing and pH 6.5
for joining, although the ranges were fairly broad.
Side-by-side comparison of ASV and HIV-1 IN joining 
activities with Mn++ or Mg++ as the metal cofactor
Although the physiologically relevant cofactor for retrovi-












÷ 1AIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
Page 6 of 10
(page number not for citation purposes)
and HIV-1 IN proteins are reported to be more active with
Mn++ as the cofactor. For comparison of the activities of
these proteins, as donor oligodeoxynucleotides we used
sequences from the U3 (ASV IN) and U5 (HIV-1 IN) LTRs,
because previous studies have shown that the enzymes are
most active with these DNA ends [18,19]. The ratio of IN
to donor DNA was 2:1 as preliminary experiments indi-
cated that this was close to the optimum for both
enzymes. To accommodate the differences noted above,
the ASV IN reactions were run at pH 8.0 and the HIV-1 IN
reactions at pH 7.3 in which joining was expected to be
close to optimal with both metals. When analyzed under
these conditions, the initial rate for joining by ASV IN
with Mn++ as the cofactor was 6.7 times faster than HIV-1
Tests of the metal cofactor effects of HIV-1 IN inhibitors on HIV-1 and ASV IN joining activities Figure 4
Tests of the metal cofactor effects of HIV-1 IN inhibitors on HIV-1 and ASV IN joining activities. A. Dose 
response curves showing the joining activities of HIV-1 and ASV IN (at 1 μM concentration) as a function of increasing concen-
tration of compound 1. Triplicate data are plotted for each inhibitor concentration and the curves show non-linear regression 
fitting of the data using Visual Enzymics software. The solid and open triangles represent HIV-1 IN activity in the presence of 
Mn++ or Mg++ cofactors, respectively. The solid and open squares represent ASV IN activity in the presence of Mn++ or Mg++ 
cofactors, respectively. B. Comparison of the IC50 values obtained by gel and solution based methods. The structure of the 
inhibitors is shown to the left of the table. Previously published values for IC50s with HIV-1 IN are shown on the left, while val-
ues on the right for both HIV-1 and ASV IN were obtained with the solution assay described here. The latter values were 
determined from non-linear fitting of the triplicate data to a four parameter sigmoidal dose response equation, with the stand-
ard error of the fit shown for compounds 1 and 3. Data for compound 2 are from a single experiment.AIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
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IN, and with Mg++ it was 5.3 times faster (Figure 2B). With
both enzymes, the initial rates in the presence of Mg++
were 30 to 40 percent of that with Mn++. In both cases, the
initial "burst" of product in the presence of Mg++ leveled
off rather quickly (within 5 to 15 min), and then product
continued to increase at a much reduced rate. A similar
response was observed in the presence of Mn++, but the
rate of the second phase was higher. In both cases, the ini-
tial bursts are likely to represent product from donor-
enzyme complexes formed during the preincubation step
(Figure 2A, Step 1). The subsequent, reduced rates reflect
the slow turnover characteristic of these enzymes, and
competition between donor and target oligodeoxynucle-
otides for enzyme binding in subsequent rounds of catal-
ysis. Similar effects have been noted in studies of joining
by ASV IN [20]. In the case of ASV, we observed an appar-
ent decrease in the amount of product after 50 min (Fig-
ure 2B, inset), which may be explained by the increased
non-specific nuclease activity of this enzyme in the pres-
ence of Mn++ [21].
The joining assay can also be used with non-recessed,
blunt-ended donor oligodeoxynucleotides. However,
such a donor end must first be processed by IN before it
can be joined to the target oligodeoxynucleotide. Figure
2C shows a comparison of the joining activities of ASV IN
with recessed and blunt-ended donor DNAs, in the pres-
ence of Mg++. The initial rate with the blunt ended donor
is less than half that observed with the recessed end
donor, indicating that the overall reaction rate is limited
substantially by processing. Guiot et al. [14] have shown
that the rate of processing by HIV-1 IN is also relatively
slow.
Joining activity is confirmed by polyacrylamide gel 
electrophoresis
To verify that joining has indeed taken place in the context
of this assay, we added a radioactive (32P) label to the 5'
end of the donor strand to be joined, and then analyzed
the products using gel electrophoresis. The donor and tar-
get oligodeoxynucleotides in these reactions were other-
wise identical to those used in our standard fluorescence
assay (Figure 2B), and the sequences are shown in Figure
3. As controls, we also prepared and tested radioactively
labeled ASV donor oligodeoxynucleotides that lacked
either the A of the conserved CA, or both nucleotides.
Results from two time points were analyzed in each case.
As illustrated in the gel data (Figure 3 right), joined prod-
ucts were detected in both the HIV-1 and ASV IN reactions
with the respective donor oligodeoxynucleotides, in the
same relative proportions as determined in the fluores-
cence assay. As expected from numerous previous studies,
severely reduced joining was observed with the donors
that lacked one or both of conserved, terminal CA dinu-
cleotides.
Table 1 shows a comparison of signal-to-background
ratios calculated for the same time points in the experi-
ments of Figure 2B and Figure 3, as well as from previous
gel analyses (not shown). These data indicate that the flu-
orescence-based joining assay is approximately 20–30
times more sensitive than the gel assay in reactions cata-
lyzed by either enzyme in the presence of Mn++. With
Mg++ as cofactor, the increase in sensitivity is at least 10-
fold for HIV-1 IN, and approximately 20-fold for ASV IN.
Data from the fluorescence joining analyses in Figure 2B
were also used to calculate the signal to noise ratio, which
is a more statistically significant measure of the quality of
an assay, as it includes standard deviation of the back-
ground as a parameter [22]. Values obtained for ASV IN
were 169 with Mn++ (15 min) and 205 with Mg++ (30
min).
Use of the fluorescence-based joining assay for 
identification of HIV-1 IN inhibitors that are effective 
against ASV IN
We were also interested in evaluating the utility of the flu-
orescent assay for determining IC50 values for integrase
inhibitors. In this context, Zhao et al [23] recently
reported the development of a number of novel metal
chelating inhibitors of HIV-1 IN, several of which were
found to be effective in blocking both processing and
joining in the presence of either Mn++ or Mg++. Of special
interest for our analyses, was a related series of 2,3-dihy-
droxybenzoic acid hydrazides (Figure 4B) [23-25]. Com-
pound 1, is a symmetrical molecule reported to block
both the processing and joining activities of HIV-1 IN,
with either metal cofactor. In compound 2, one hydroxyl
on the left benzoyl ring is substituted with a methoxyl
group, a change that was reported to have little effect on
the inhibitory potency for HIV-1 IN with Mn++, but
Table 1: Comparison of signal to background ratios for 
fluorescence-based and gel joining assays
HIV-1 IN ASV IN
Cofactor Assay 60' 120' 15' 30'
Mn++ a. Fluorescence 61 78 126 155
b. Gel 2.5 3.4 4.2 4.5
Fold Difference (a/b) 24.4 23 30 34
Mg++ c. Fluorescence 21.4 26.5 26.3 31.3
d. Gel* -- 2.6* -- 1.3*
Fold Difference (c/d) 10 24
Signal-to-background ratios were calculated by dividing the values 
obtained in the presence of IN by those obtained in the absence of IN 
in the released fluorescent product (Figure 2B) or the relevant region 
of the gel (Figure 3). Ratios marked with an asterisk are from previous 
gel assays (not included), with ASV IN at the indicated time and HIV-1 
IN at 180'.AIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
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resulted in reduced potency with Mg++. Removal of the
same hydroxyl to produce compound 3 also had little
effect in Mn++, but the potency in Mg++ was reduced even
further. We tested these compounds for cofactor-depend-
ent activity against both HIV-1 and ASV IN proteins at 1
μM concentration, using our fluorescence joining assay
(Figure 4).
The concentration dependence for compound 1 inhibi-
tion of joining by HIV-1 and ASV IN proteins is shown in
Figure 4A. As reported previously [23], HIV-1 IN is almost
equally sensitive to this compound in the presence of
either metal cofactors. Similar inhibition is seen for ASV
IN with this inhibitor in the presence of Mn++, but ASV IN
is much more resistant to this compound in the presence
of Mg++. It is noteworthy that with both enzymes the
slopes of the dose response curves is steeper in the pres-
ence of Mn++ (Hill coefficient of 2–2.5) than Mg++ (0.6–
1.3). This is indicative of a greater cooperativity of inhibi-
tor binding with the Mn++ cofactor, and is consistent with
results from previous studies of this class of inhibitors
[17]. The Z' factor [22] calculated from the assays per-
formed in these experiments was 0.7, which represents a
"good" value for screening fitness.
A summary of the IC50 values calculated for all three
inhibitors is shown in Figure 4B. The results from the flu-
orescence joining assays with HIV-1 IN generally corre-
spond to those reported for the gel assays, thus validating
its utility for such studies. These analyses show that ASV
IN is slightly (~2–5-fold) less sensitive than the HIV-1
enzyme to inhibition by these compounds in the presence
of Mn++. From these results, it appears that in the presence
of this metal cofactor, all three compounds interact with
structural elements that are conserved in these two IN pro-
teins, and this interaction inhibits the joining reaction.
Results with compound 1 indicate that this inhibitor is




In this report we describe a simplified assay measuring the
joining activity for retroviral integrases in solution. The
assay offers several advantages over the gel analyses used
in many laboratories. Limitations of the gel assays include
the length of time needed to separate and quantify the
products and relatively low sensitivity. The latter problem
derives from the fact that the ligated products detected in
this assay are of different sizes and therefore spread
through a large portion of the gel (see Figure 3), such that
backgrounds can be a problem. In the solution assay we
have developed, the uniformly sized, non-ligated viral
donor strand is scored in each reaction. Our signal to
background calculations (Table 1) indicate that the fluo-
rescence assay is approximately 10–30 times more sensi-
tive than the standard gel assay for measuring this activity.
In addition, the assay is much faster than gel analysis and
numerous samples can be handled with relative ease.
The assay described here builds upon features introduced
by several investigators in earlier efforts to facilitate anal-
ysis of the joining reaction both for biochemical studies
and identification of inhibitors. The use of biotin in com-
bination with streptavidin-coated plates or beads, as well
as magnetic beads, to select joined products has been
described previously in our lab and others [20,26-29].
Reporters for the recombination products have included
radioactivity [20,26] and digoxygenin plus a conjugated
antibody that allows amplification of the signal [27-29].
However, most of these previously described methods
require more steps than our assay and, in some cases, the
reactions are designed to take place on a solid surface [29-
31], which is well-suited for high throughput screening of
inhibitors but not for biochemical analyses. Furthermore,
the shelf life of the fluorescent substrates is not limited by
radioactive decay.
For our standard assay, we chose carboxyfluorescein as a
reporter because the signal can be detected easily and
directly in a plate reader. This reporter was used exten-
sively by Deprez and coworkers in the development of flu-
orescence-based assays for DNA binding and processing
by IN [14,32], which we have found to be extremely use-
ful. Together with our joining assay, they provide a con-
venient fluorescence-based suite of methods with which
to analyze the properties of IN proteins using the same
detection system [15]. However, if necessary, the sensitiv-
ity of the assay could be increased further by use of other
reporters such as radioactivity or digoxygenin plus anti-
body for amplification. Finally, the assay can be adapted
for measuring disintegration, i.e. reversal of the joining
reaction (Figure 1B) [33,34].
The novel elements of our joining assay are 1) the place-
ment of the reporter on the donor strand complementary
to that which is actually joined, and its dissociation from
the bound product and 2) the attachment of biotin to the
3' ends of both strands of the target DNA. The first feature
allows for better detection of the reporter, as its signal is
obscured when retained on agarose beads. After develop-
ing this protocol we discovered that a similar strategy was
employed by Landgraf et al. [35] in development of a
quantitative assay for PCR products. The advantage of
having biotin on both strands of the target DNA is that
products of joining to either target DNA strand will be
captured, thereby improving sensitivity. At present this
assay is suitable for moderate throughput applications, as
reactions are run in separate tubes. This is adequate for
routine laboratory research, but the method could beAIDS Research and Therapy 2009, 6:14 http://www.aidsrestherapy.com/content/6/1/14
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modified for higher throughput and inhibitor screening,
if desired. In the latter case, a reporter other than carboxy-
fluorescein might be more useful, as candidate inhibitors
that exhibit intrinsic fluorescence could increase the back-
ground.
The similarities and differences in the cofactor responses 
with HIV-1 and ASV IN
A side-by-side detailed comparison of the cofactor-
dependent joining activities of purified HIV-1 and ASV IN
proteins used to illustrate the utility of this new assay
revealed a number of similarities, as well as some notable
differences. Although Mg++ is likely to be the biologically-
relevant cofactor, the initial rates of joining by both iso-
lated enzymes with Mg++ are less than half the rate, with
Mn++. Both enzymes also exhibit a similar pH optimum
(7–7.5) in the presence of Mn++. However, with ASV IN,
the optimum for joining in Mg++ is somewhat higher (pH
8–8.5), and with HIV-1 IN lower (pH 7–6.5) than with
Mn++. The reason for these differences is unknown, but
these data suggest that the two metals are bound differ-
ently by these enzymes, and/or that the microenviron-
ment for binding Mg++ is not the same in the two proteins.
Finally, the rate of joining by ASV IN is 6–7 fold faster
than HIV-1 IN in the presence of either metal cofactor.
We also demonstrated the utility of the joining assay for
screening inhibitors, by testing the potency of a related
series of compounds known to block HIV-1 IN, on the
activities of both IN proteins. The IC50 values obtained
with HIV-1 IN were similar to those previously reported
with a gel assay, despite the fact that our assay conditions
are quite different [36]. We also observed that, like HIV-1,
ASV IN was sensitive to inhibition by all three compounds
in the presence of Mn++, although the IC50 values were
approximately 2 to 5 times higher with this enzyme. This
finding is consistent with the notion that Mn++ is bound
in similar ways by these two proteins. Inhibitor 1 was of
special interest as it was reported to be equally effective
with HIV-1 IN in the presence of either metal cofactor,
and those results were also confirmed by our assay. Our
finding that this compound was ineffective against ASV IN
in the presence of Mg++, further supports the notion that
the determinants for binding of Mg++, or a Mg++-inhibitor
complex, are different in the two enzymes.
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